Form D · Pharmaceuticals
TelyRx Finco Inc.
Toronto, A6 · CIK 0002125491
Offering snapshot reported Apr 20, 2026 · SEC filing
- Reported sold
- $12.6M Offering amount: $12.6M
- Investors reported
- 51 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 26, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 20, 2026 | Initial | $12,623,935 | No comparison | 51 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $394K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-581152
Subscription receipts exchangeable for common shares without further consideration upon satisfaction of certain conditions.
C$1.3694=US$1.00
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Canaccord Genuity Corp. | None | Canaccord Genuity LLC · CRD 000001020 |
Source: Form D, filed Apr 20, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Eric Cascio | Director, Executive |
| Vanessa Slowey | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
333 Bay Street, Suite 2400
Toronto, A6, M5H 2T6
Phone: 800-878-1660
Toronto, A6, M5H 2T6
Phone: 800-878-1660